Imeglimin: Finding a Place in Modern Diabetes Pharmacotherapeutics

Main Article Content

Sanjay Kalra
Saptarshi Bhattacharya
Shehla Shaikh


Type 2 diabetes mellitus (T2DM) is a multifactorial disease. Newer facets of its causation, clinical course, complications and therapy are being unraveled regularly. This editorial describes imeglimin, a first-of-class oxidative phosphorylation inhibitor, that has been approved for T2DM in Japan and India.


Download data is not yet available.

Article Details

Clinical Perspectives

Most read articles by the same author(s)

1 2 > >>